Clinical Trial

Liposomal Bupivacaine and Transoral Robotic Surgery

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is for patients with oropharyngeal squamous cell carcinoma. We want to learn more about how we can optimize pain control in patients who undergo transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma. Our goal is to determine if a local anesthetic called EXPAREL® (Liposomal Bupivacaine) impacts postsurgical pain and swallow function in patients with oropharyngeal squamous cell carcinoma undergoing TORS. EXPAREL® is an FDA-approved anesthetic drug that provides long-lasting and precise pain relief when injected into the surgical wound. Our study team wants to determine if injecting EXPAREL® into the surgical wound will provide better pain relief and swallow function when compared to patients who do not undergo postoperative EXPAREL® injection. Both options for postoperative pain control are considered standard of care for patients undergoing TORS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-08; most recent amendment 2025-09-05.
Status change: Not Yet Recruiting → Recruiting 2023-11-01
Trial Details
NCT Number NCT05862792
Lead Sponsor Geisinger Clinic
Conditions Oropharyngeal Cancer, Dysphagia, Oropharyngeal, Post Operative Pain, Transoral Robotic Surgery
Enrollment 80 participants
Start Date 2023-06-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2025-09-09